Assessment of Colonisation and Skin Quality Parameter Improvement by Probiotic Micrococcus Luteus Q24 Balm in Healthy Adults.

Last updated: February 20, 2023
Sponsor: BLIS Technologies Limited
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT05750381
BLTCT2022/8
  • Ages 18-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to evaluate the skin quality improvement and colonization efficacy following the application of probiotic Micrococcus luteus Q24 (BLIS Q24) to the elbow and back of forearm in a topical balm format in healthy adults.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • In general good health 18 - 80 years of age.
  • Practice good general body hygiene

Exclusion

Exclusion Criteria:

  • Have a history of autoimmune disease or are immunocompromised.
  • Are on concurrent antibiotic therapy or regular antibiotic use within the last 1 week.
  • People with allergies or sensitivity to dairy.
  • People with an open wound on the Blis Q24 application sites.

Study Design

Total Participants: 20
Study Start date:
January 24, 2023
Estimated Completion Date:
April 12, 2023

Study Description

This is a randomized double-blind, placebo-controlled pilot study with no crossover for the assessment of any changes to the microbial make-up of the skin (The local skin microbiome), detection of colonisation by the probiotic bacterium (BLIS Q24) on the skin and to evaluate the changes in skin quality parameters following topical application of probiotic in a balm format.

Connect with a study center

  • Blis Technologies Ltd

    Dunedin, Otago 9012
    New Zealand

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.